Search
English
中文
About Us
At a Glance
History and Milestones
Global Recognition
Management Team
Research & Development
Oncology
Autoimmune Diseases
Facility and Capacity
Products
Pipeline Overview
HMPL-004
HMPL-011
Sulfatinib
Fruquintinib
HMPL-813
Collaborations
Collaboration Overview
Existing Partnerships
Media
Key Facts
Press Releases
Featured Articles
Careers
Contacts
About Us
Hutchison Medi Pharma is an entrepreneurial, China-based, global quality drug development company with a rich pipeline, first class R&D leadership and a proven track record.
Product Pipeline
With a rich and unique pipeline in oncology and autoimmune disease, the Company has compounds in pre-clinical, phase I, phase II and phase III development in the US, Europe, Australia and China.
Latest News
03/01/2012
HMP initiates Phase I clinical study of its novel c-Met inhibitor Volitinib
12/21/2011
AstraZeneca and Hutchison Medi Pharma Enter into Global Collaboration to Co-Develop and Commercialize Novel Cancer Therapy
Recent Awards
